文献速递心律失常

突变型KCNJ3和KCNJ5钾通道作为心动过缓与心房颤动的新分子靶点

Mutant KCNJ3 and KCNJ5 Potassium Channels as Novel Molecular Targets in Bradyarrhythmias and Atrial Fibrillation.
PubMed 文献 · Circulation · 2019-01-01

研究对一个含7例常染色体显性心动过缓(窦房结功能障碍、房颤伴缓慢心室率、房室传导阻滞)的家系行全外显子测序和连锁分析,发现KCNJ3 c.247A>C p.N83H突变;该突变使IKACh通道功能增强,选择性阻断剂NIP-151可改善突变斑马鱼的心动过缓表型。

要点

  • KCNJ3 p.N83H是遗传性心动过缓的新致病突变,导致IKACh通道功能增强。
  • 在2185例散发性房颤队列中另发现KCNJ3和KCNJ5的5个罕见突变。
  • 选择性IKACh阻断剂NIP-151可抑制突变通道电流并改善斑马鱼心动过缓表型。

核心结论

  • IKACh通道参与心动过缓和心房颤动的病理生理过程,突变型IKACh通道(KCNJ3 p.N83H)可被NIP-151有效抑制。
  • IKACh通道可能作为伴有功能获得性突变的迟缓心律失常患者的药物治疗靶点。

研究设计与样本

  • 研究一个含7例常染色体显性心动过缓(窦房结功能障碍、房颤伴缓慢心室率、房室传导阻滞)的家系。
  • 采用家系全外显子测序和全基因组连锁分析鉴定致病突变。
  • 基于体外病理生理学表征突变相关机制,并构建转基因动物模型确认人类心动过缓表型。
  • 利用动物模型评估新发现的分子靶向化合物上调心率的效果。

主要发现

  • 鉴定出KCNJ3 c.247A>C p.N83H杂合突变为该家系遗传性心动过缓的新病因。
  • KCNJ3编码内向整流钾通道Kir3.1,与Kir3.4(由KCNJ5编码)结合形成心房特异性表达的乙酰胆碱激活钾通道(IKACh通道)。
  • 在2185例散发性房颤基因组队列中另发现KCNJ3和KCNJ5的5个罕见突变,提示两基因与这些心律失常相关。
  • 细胞电生理研究显示KCNJ3 p.N83H突变即使无m2毒蕈碱受体刺激,也通过增加基础电流导致IKACh通道功能获得。
  • 在心脏心房特异性表达突变人类KCNJ3的转基因斑马鱼中,选择性IKACh通道阻断剂NIP-151抑制增加的电流并改善心动过缓表型。

临床怎么用

  • 对于遗传性心动过缓患者,可考虑KCNJ3和KCNJ5基因检测以明确分子病因。
  • IKACh通道功能获得性突变患者可能从选择性IKACh通道阻断剂(如NIP-151)治疗中获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bradyarrhythmia is a common clinical manifestation. Although the majority of cases are acquired, genetic analysis of families with bradyarrhythmia has identified a growing number of causative gene mutations. Because the only ultimate treatment for symptomatic bradyarrhythmia has been invasive surgical implantation of a pacemaker, the discovery of novel therapeutic molecular targets is necessary to improve prognosis and quality of life. METHODS: We investigated a family containing 7 individuals with autosomal dominant bradyarrhythmias of sinus node dysfunction, atrial fibrillation with slow ventricular response, and atrioventricular block. To identify the causative mutation, we conducted the family-based whole exome sequencing and genome-wide linkage analysis. We characterized the mutation-related mechanisms based on the pathophysiology in vitro. After generating a transgenic animal model to confirm the human phenotypes of bradyarrhythmia, we also evaluated the efficacy of a newly identified molecular-targeted compound to upregulate heart rate in bradyarrhythmias by using the animal model. RESULTS: We identified one heterozygous mutation, KCNJ3 c.247A>C, p.N83H, as a novel cause of hereditary bradyarrhythmias in this family. KCNJ3 encodes the inwardly rectifying potassium channel Kir3.1, which combines with Kir3.4 (encoded by KCNJ5) to form the acetylcholine-activated potassium channel ( IKACh channel) with specific expression in the atrium. An additional study using a genome cohort of 2185 patients with sporadic atrial fibrillation revealed another 5 rare mutations in KCNJ3 and KCNJ5, suggesting the relevance of both genes to these arrhythmias. Cellular electrophysiological studies revealed that the KCNJ3 p.N83H mutation caused a gain of IKACh channel function by increasing the basal current, even in the absence of m2 muscarinic receptor stimulation. We generated transgenic zebrafish expressing mutant human KCNJ3 in the atrium specifically. It is interesting to note that the selective IKACh channel blocker NIP-151 repressed the increased current and improved bradyarrhythmia phenotypes in the mutant zebrafish. CONCLUSIONS: The IKACh channel is associated with the pathophysiology of bradyarrhythmia and atrial fibrillation, and the mutant IKACh channel ( KCNJ3 p.N83H) can be effectively inhibited by NIP-151, a selective IKACh channel blocker. Thus, the IKACh channel might be considered to be a suitable pharmacological target for patients who have bradyarrhythmia with a gain-of-function mutation in the IKACh channel.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Yamada N, Asano Y, Fujita M, et al. Mutant KCNJ3 and KCNJ5 Potassium Channels as Novel Molecular Targets in Bradyarrhythmias and Atrial Fibrillation. Circulation. 2019. PMID: 30764634. doi:10.1161/CIRCULATIONAHA.118.036761

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。